Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Digicann VenturesAGFAF Debt-to-EBITDA is 2.93 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 681 Drug Manufacturers companies, Digicann Ventures ranks worse than 146842.73% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Digicann Ventures's Debt-to-EBITDA or its related term are showing as below:
AGFAF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.35 Med: -0.36 Max: 2.91
Current: -7.35
During the past 13 years, the highest Debt-to-EBITDA Ratio of Digicann Ventures was 2.91. The lowest was -7.35. And the median was -0.36.
AGFAF's Debt-to-EBITDA is ranked worse than 100% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs AGFAF: -7.35
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Digicann Ventures Debt-to-EBITDA Related Terms
Digicann Ventures Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Digicann Ventures's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGFAF vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Digicann Ventures's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Digicann Ventures Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Digicann Ventures's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Digicann Ventures's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Digicann Ventures (AGFAF) has a Debt-to-EBITDA of 2.93 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Digicann Ventures. According to the industry distribution chart, Digicann Ventures ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Digicann Ventures' Debt-to-EBITDA too high?
Digicann Ventures' current Debt-to-EBITDA is 2.93. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Digicann Ventures' value of 2.93 is 79.8% above this industry median. Based on the distribution chart, Digicann Ventures ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Digicann Ventures' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Digicann Ventures ranks #999999 out of 681 companies for Debt-to-EBITDA. This places Digicann Ventures in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Digicann Ventures' value of 2.93 is 79.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Digicann Ventures's current Debt-to-EBITDA of 2.93 is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Digicann Ventures. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Digicann Ventures's current Debt-to-EBITDA is 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Digicann Ventures stock overvalued right now?
Digicann Ventures (AGFAF) has a current Debt-to-EBITDA of 2.93. The current Debt-to-EBITDA is 2.93 and 79.8% above the Drug Manufacturers industry median of 1.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Digicann Ventures (AGFAF), the current Debt-to-EBITDA is 2.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Digicann Ventures Inc is a company focused on opportunities within and outside of the cannabis industry. The company focuses on identifying new business opportunities and operates in a single geographic location in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGFAF has been successfully added to your 
